Holen Sie sich die Stockscreener-App
0.5807
4.02%
-0.0243
Handel nachbörslich:
.58
-0.0007
-0.12%
Schlusskurs vom Vortag:
$0.605
Offen:
$0.63
24-Stunden-Volumen:
35,111
Relative Volume:
0.15
Marktkapitalisierung:
$2.84M
Einnahmen:
$14.64M
Nettoeinkommen (Verlust:
$-13.74M
KGV:
-0.0799
EPS:
-7.27
Netto-Cashflow:
$-5.04M
1W Leistung:
-11.64%
1M Leistung:
-12.58%
6M Leistung:
+19.83%
1J Leistung:
-89.12%
1-Tages-Spanne:
$0.5807
$0.63
1-Wochen-Bereich:
$0.58
$0.6388
52-Wochen-Spanne:
$0.3611
$9.079
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Firmenname
Novabay Pharmaceuticals Inc
Sektor
Branche
Telefon
510-899-8800
Adresse
2000 Powell Street, Suite 1150, Emeryville, CA
Vergleichen Sie NBY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBY
Novabay Pharmaceuticals Inc
|
0.5807 | 2.84M | 14.64M | -13.74M | -5.04M | -7.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-09-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Bestätigt | Laidlaw | Buy |
| 2017-06-05 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-27 | Eingeleitet | Laidlaw | Buy |
| 2017-02-06 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-03-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-12-14 | Bestätigt | Maxim Group | Buy |
| 2015-04-30 | Fortgesetzt | Maxim Group | Buy |
| 2013-03-06 | Eingeleitet | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | Eingeleitet | Dawson James | Speculative Buy |
Alle ansehen
Novabay Pharmaceuticals Inc Aktie (NBY) Neueste Nachrichten
StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - ACCESS Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
NovaBay extends CEO's contract through 2025 - MSN
StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? - Armenian Reporter
NovaBay fails to gain shareholder approval for dissolution - MSN
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - ETF Daily News
NovaBay fails to gain shareholder approval for dissolution By Investing.com - Investing.com Canada
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
**NovaBay Pharmaceuticals Completes Asset Sale Transaction and Plans for Dissolution**** - Defense World
NovaBay Pharmaceuticals Completes the Sale of its Avenova Eyecare Business to PRN, Seeks Full Company Dissolution - Vision Monday
NovaBay Pharma’s Strategic Shift and Liquidation Plans - TipRanks
NovaBay Completes $11.5M Avenova Sale to PRN, Pursues Full Company Dissolution - StockTitan
NovaBay Pharmaceuticals Extends CEO’s Employment Agreement Until 2025 - Defense World
NovaBay extends CEO's contract through 2025 By Investing.com - Investing.com South Africa
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com - Defense World
NovaBay Pharmaceuticals Completes Sale of Wound Care Product Trademarks and Inventory - Defense World
Novabay Pharmaceuticals Announces Board Changes - Marketscreener.com
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Cross Above 50 Day Moving Average – Should You Sell? - Defense World
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com - Defense World
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why - Yahoo Finance
NovaBay Pharmaceuticals Adjourns Special Meeting Due to Insufficient Votes - Defense World
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders - BioSpace
NovaBay Pharmaceuticals Delays Critical Vote on Avenova Sale and Company Dissolution Amid Vote Shortage - StockTitan
NovaBay®Pharmaceuticals, Inc. Launches NovaWipes Eyelid Wipes on Amazon.com - Marketscreener.com
NBYNovaBay Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting - BioSpace
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 - BioSpace
NovaBay Postpones Key Vote on Asset Sale, Liquidation Plans Amid Low Turnout | NBY Stock News - StockTitan
NovaBay calls for affirmative vote on asset sale and dissolution - Investing.com
NovaBay calls for affirmative vote on asset sale and dissolution By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes - TipRanks
Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder - Reuters
NovaBay Pharmaceuticals Reports Third Quarter 2024 Results, Accepts Revised Offer to Sell Avenova Brand - Vision Monday
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
NovaBay accepts higher PRN offer, says Refresh deal no longer superior - MSN
NovaBay agrees to increased offer for eyecare unit - Investing.com
NovaBay agrees to increased offer for eyecare unit By Investing.com - Investing.com UK
Finanzdaten der Novabay Pharmaceuticals Inc-Aktie (NBY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.13%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):